10-K/A: Amedisys Files Amendment No. 2 to Form 10-K for Fiscal Year Ended December 31, 2024, Addressing Part III Information
10-K/A Filing
Amedisys files Amendment No. 2 to its Form 10-K to include information required by Part III and updated certifications from the CEO and CFO.
Summary
- Amedisys has filed Amendment No. 2 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
- The amendment primarily includes information required by Part III of Form 10-K, which covers details about directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and principal accountant fees.
- The filing also includes currently dated certifications from the company's principal executive officer and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- The original Form 10-K speaks as of its original filing date, and this amendment does not reflect events occurring after that date or update the disclosures therein, except to reflect the amendments discussed.
- As of April 25, 2025, the registrant had 32,819,638 shares of Common Stock outstanding.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing, so the sentiment is neutral. The information is factual and doesn't convey any strong positive or negative outlook.
Industry Context
This is a standard regulatory filing update to comply with SEC requirements for annual reporting.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Legal Officer | Interim Chief Legal Officer | Jennifer Griffin | November 4, 2024 | Promotion |
Key Dates
| Date | Description |
|---|---|
| 2002 | Sarbanes-Oxley Act of 2002 |
| June 28, 2024 | Date used to determine the aggregate market value of voting and non-voting common stock held by non-affiliates of the registrant |
| December 31, 2024 | Fiscal year end date for the Form 10-K |
| February 27, 2025 | Filing date of Amendment No. 1 to Form 10-K |
| April 25, 2025 | Date of outstanding shares of Common Stock |
| April 29, 2025 | Date of Amendment No. 2 filing and certifications |
Keywords
Form 10-K, amendment, directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, accountant fees, Amedisys
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.